Implementation of Standardized Early Identification and Diagnosis for Transthyretin Amyloidosis (ATTR) in High-Risk Populations
← catalyst calendarNCT07338942 · readout in 458 d
Sponsored by AstraZeneca (industry) · AZN — their whole pipeline →.
Phase
Not applicable
Status
Active, not recruiting
Study type
Interventional
Design
Na · None · Screening
Enrollment
4,000estimated
Sites
48
Country
China
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-04-21 | actual | When the study began enrolling |
| Primary completion | 2027-11-20 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-11-20 | estimated | The whole study's end, after follow-up |
| First posted | 2026-01-14 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-07 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- ATTR-CM
Intervention
- Behavioral: implementation of standard early identification and diagnosis of ATTR
Primary outcome
what the primary-completion date above is the date OFProportion of patients diagnosed with ATTR in high-risk population.
measured Week 14
Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed